News
Displaying 261–270 of 508
-
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
Research NewsThe emerging therapy is designed to work independent of the mutated gene causing vision loss
-
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
Research NewsThe company is also expanding its Phase ½ trial for the emerging treatment
-
Foundation News
Accepting grant applications for advancing retinal degeneration treatments toward human studies
-
Research News
A Phase 3 trial for the treatment is planned
-
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
Research NewsThe goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial
-
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Research NewsTreatment combines gene therapy and a device that generates and delivers retinal code
-
Foundation Fighting Blindness to Host Virtual VISIONS 2020 Conference
Foundation NewsThe national conference will be held virtually on June 25-27, providing the latest in science and research, practical adapting and thriving, and an opportunity to connect with others who are visually impaired.
-
Research News
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Genentech’s Port Delivery System for Wet AMD Meets Primary Endpoint in Phase 3 Clinical Trial
Research NewsTiny implant provides continual delivery of anti-VEGF treatment for six months
-
Abfero Targeting Excess Iron to Treat AMD, Other Retinal Diseases
Partner NewsAn intriguing link between excess body iron and retinal degeneration is being explored by Abfero Pharmaceuticals, a young biotech based in Boston and Oxford, UK.
